Oryzon GenomicsORYZF 31 14-Day RSI is 71.88 as of Jul. 04, 2026. GuruFocus rates ORYZF with a GF Score™ of 31/100. Among 1,423 Biotechnology companies, Oryzon Genomics ranks better than 67.96% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-04), Oryzon Genomics's 14-Day RSI is 71.88.
The industry rank for Oryzon Genomics's 14-Day RSI or its related term are showing as below:
ORYZF's 14-Day RSI is ranked better than 67.96% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs ORYZF: 71.88
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Oryzon Genomics 14-Day RSI Related Terms
ORYZF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Oryzon Genomics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oryzon Genomics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oryzon Genomics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Oryzon Genomics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oryzon Genomics (ORYZF) has a 14-Day RSI of 71.88 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oryzon Genomics and its competitors. According to the industry distribution chart, Oryzon Genomics ranks #456 out of 1423 companies in the Biotechnology industry, placing it in the top 32%.
Is Oryzon Genomics' 14-Day RSI too high?
Oryzon Genomics' current 14-Day RSI is 71.88. The Biotechnology industry median 14-Day RSI is 49.99. Oryzon Genomics' value of 71.88 is 43.8% above this industry median. Based on the distribution chart, Oryzon Genomics ranks #456 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #456 out of 1423 companies for 14-Day RSI. This puts Oryzon Genomics in the upper half of its industry. The industry median 14-Day RSI is 49.99. Oryzon Genomics' value of 71.88 is 43.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oryzon Genomics's current 14-Day RSI of 71.88 is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oryzon Genomics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current 14-Day RSI is 71.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (ORYZF) has a current 14-Day RSI of 71.88. The current 14-Day RSI is 71.88 and 43.8% above the Biotechnology industry median of 49.99. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Oryzon Genomics (ORYZF), the current 14-Day RSI is 71.88 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score
Get the complete analysis for ORYZF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORYZF has been successfully added to your 